Literature DB >> 15063389

Cyclin D1 gene polymorphism as a risk factor for squamous cell carcinoma of the upper aerodigestive system in non-alcoholics.

Ines Nobuko Nishimoto1, Nidia Alice Pinheiro, Silvia Regina Rogatto, André Lopes Carvalho, Andrew J Simpson, Otávia Luisa Caballero, Luiz Paulo Kowalski.   

Abstract

Squamous cell carcinoma of the upper aerodigestive tract (UADT) is associated with environmental factors, especially tobacco and alcohol consumption. Genetic factors, including cyclin D1 (CCND1) polymorphism have been suggested to play an important role in tumorigenesis and progression of UADT cancer. To investigate the relationship between CCND1 polymorphism on susceptibility for UADT cancers, 147 cancer and 135 non-cancer subjects were included in this study. CCND1 genotype at codon 242(G870A) in exon 4 was undertaken using denaturing high performance liquid chromatography (DHPLC) and DNA sequencing. Significant odds ratio (OR) of the AA+GA genotypes [OR=7.5 (95% CI: 1.4-39.7)] was observed in non-drinkers but for non-smokers a non-significant [OR=5.4 (95% CI: 0.9-31.4)] was found in the adjusted model. These results suggest that allele A may be a risk factor for UADT cancer, especially in non-alcoholics. However, further epidemiological studies are needed to establish the exact role of CCND1 polymorphism and the development of UADT cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063389     DOI: 10.1016/j.oraloncology.2003.12.009

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  9 in total

1.  CCND1 G870A polymorphism and risk for head and neck cancer: a meta-analysis.

Authors:  Chunbo Tang; Zhanwei Wang; Jinhua Yu; Yunong Wu; Zhijun Zhu; Ning Chen
Journal:  Med Oncol       Date:  2010-05-05       Impact factor: 3.064

2.  Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx.

Authors:  Malgorzata Rydzanicz; Pawel Golusinski; Daniela Mielcarek-Kuchta; Wojciech Golusinski; Krzysztof Szyfter
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-10-29       Impact factor: 2.503

3.  G870A Polymorphic Variants of CCND1 Gene and Cyclin D1 Protein Expression as Prognostic Markers in Laryngeal Lesions.

Authors:  Magdalena Marianna Kowalczyk; Magda Barańska; Wojciech Fendler; Edyta M Borkowska; Józef Kobos; Maciej Borowiec; Wioletta Pietruszewska
Journal:  Diagnostics (Basel)       Date:  2022-04-23

4.  Cyclin D1 polymorphism and oral cancer: a meta-analysis.

Authors:  Wenjun Wang; Yuming Zhao; Jie Yang; Bichen Lin; Haiyong Gu; Xiaoqing Cao; Lihong Ge
Journal:  Mol Biol Rep       Date:  2012-10-31       Impact factor: 2.316

5.  Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis.

Authors:  Lili Wang; Zhiying Wang; Xiuqiu Gao; Xin Li; Xirao Sun; Changfu Liu
Journal:  Tumour Biol       Date:  2013-11-05

Review 6.  A review of genetic epidemiology of head and neck cancer related to polymorphisms in metabolic genes, cell cycle control and alcohol metabolism.

Authors:  G Cadoni; S Boccia; L Petrelli; P Di Giannantonio; D Arzani; A Giorgio; E De Feo; M Pandolfini; P Gallì; G Paludetti; G Ricciardi
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-02       Impact factor: 2.124

7.  Association between the Cyclin D1 G870A polymorphism and the susceptibility to and prognosis of upper aerodigestive tract squamous cell carcinomas: an updated meta-analysis.

Authors:  Yichen Meng; Chenglin Zhang; Xuhui Zhou
Journal:  Onco Targets Ther       Date:  2016-01-19       Impact factor: 4.147

8.  Molecular drivers of oral cavity squamous cell carcinoma in non-smoking and non-drinking patients: what do we know so far?

Authors:  Sophia Uddin; Alka Singh; Vasudha Mishra; Nishant Agrawal; Zhen Gooi; Evgeny Izumchenko
Journal:  Oncol Rev       Date:  2022-02-22

9.  Lack of association of the cyclin D1 G870A variation with oral carcinoma risk: Evidence from 2,404 subjects.

Authors:  Xian-Lu Zhuo; Jun-Jun Ling; Hou-Yu Zhao; Yan Zhou; Yu-Feng Song; Ying-Hui Tan
Journal:  Exp Ther Med       Date:  2012-07-24       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.